Evaxion announces business update and second quarter 2026 financial results

COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces second quarter 2026 financial results.

Business highlights (since last quarterly update) Evaxion is making steady progress towards completing its strategic milestones for 2026. Highlights include: * Announcing the upcoming presentation of three-year clinical data for personalized cancer vaccine candidate EVX-01 at the ESMO Congress 2026 * Presentation of new data for EVX-04, an off-the-shelf cancer vaccine for acute myeloid leukemia (AML) * Expansion and refocusing of our R&D pipeline with EVX-05, a novel off-the-shelf therapeutic cancer vaccine program for glioblastoma * Presentation of new data for cytomegalovirus (CMV) vaccine candidate EVX-V1 * Winning the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™ * Cash runway unchanged with cash at hand to fund operations into the second half of 2027 “Progress remains strong in recent months, particularly regarding the expansion and progression of our R&D pipeline. Both EVX-04 and EVX-05 represent completely new concepts in targeting hard-to-treat cancers and are great examples of what we can do with AI-Immunology™ to identify novel, conserved cancer targets for off-the-shelf vaccines. The same is true for EVX-V1 in the infectious disease space and we are excited by the successful progress of this next-generation, multi-component CMV-vaccine program. These programs and the combined R&D pipeline show how our AI-Immunology™ platform can truly deliver product candidates, which is crucial in validating our platform and for partnerships,” says Helen Tayton-Martin, CEO of Evaxion.